Crystal Logsdon
Nurse Practitioner · Savannah, GANPI 1255885604
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $756 and has fallen 89.3% since, to $81 in 2025.
Across 69 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$297
- Novartis$218
- AstraZeneca$183
- Incyte Corporation$137
- Merck$136
- Boston Scientific$108
- plus $542 from 20 others
Across 85 payments — averaging $6637.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$564K
What the payments were for
- Food & beverage$1,52394%
- Education$996%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 7 | $297 |
| Novartis | 12 | $218 |
| AstraZeneca | 5 | $183 |
| Incyte Corporation | 3 | $137 |
| Merck | 8 | $136 |
| Boston Scientific | 1 | $108 |
| Springworks Therapeutics, Inc. | 5 | $86 |
| AbbVie | 3 | $68 |
| Amgen | 5 | $66 |
| Seagen Inc. | 3 | $52 |
| Eisai Inc. | 2 | $31 |
| Abbott | 1 | $21 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Octapharma USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Epizyme, Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $15 |
| Pfizer | 1 | $15 |
| Morphosys, US Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Myovant Sciences Inc. | 1 | $13 |
| Rigel Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$125
- AIRSUPRA$111
- WATCHMAN FLX$108
How this compares
$1,622 in reported general payments places this provider in the 80th percentile of 3,328 nurse practitioner providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 13 | $87 |
| Furosemide | 12 | $30 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Savannah
- Jessica AdkinsSavannah$226K
- Luis PoloSavannah$70K
- Wallette WidenerSavannah$20K
- Angie MoyeSavannah$14K
- Amy CarterSavannah$11K
- Mary RockwellSavannah$9K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.